19 September 2014 - Prosensa Holding, a biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has started a comprehensive programme of re-dosing drisapersen in the United States, it was reported yesterday.

The company is re-dosing the product in patients with Duchenne muscular dystrophy. The re-dosing programme in North America will include up to 72 patients across 14 sites who had participated in the drisapersen DEMAND V (Phase II) & DEMAND III (Phase III) studies.

The company regained the rights to drisapersen from its previous partner, GSK, in January 2014. The product is administered subcutaneously, with once weekly dosing. The firm aims to allow home-dosing where feasible, and cost-free transport with straightforward logistics for clinical centres, through collaboration with Greenphire and the Medical Research Network.